Clinical Trial Update: Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating veliparib (ABT-888) and VX-970 in combination with cisplatin in patients with refractory solid tumors has completed; results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• CISPLATIN (cisplatin)
• VX-970 (VX-970)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2022-01-10